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Background: Long-term clinical employment of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with
significant side effects including gastrointestinal (GI) lesions and kidney toxicity. In this paper we designed and synthesized
new imidazolyl-1,3,4-oxadiazoles and 1,2,4-triazoles by molecular hybridization of previously described anti-inflammatory
compounds in the hope of obtaining new safer analgesic and anti-inflammatory agents.
Methods: The target structures were synthesized by preparation of 5-methyl-1H-imidazole-4-carboxylic acid ethyl ester 5.
The reaction of hydrazine hydrate with this ester afforded the 5-methyl-1H-imidazole-4-carboxylic acid hydrazide 6 which
was converted to target compounds 7-15 according to the known procedures. In silico toxicity risk assessment and drug
likeness predictions were done, in order to consider the privileges of the synthesized structures as drug candidates.
Results and discussion: The analgesic and anti-inflammatory profile of the synthesized compounds were evaluated by
writhing and carrageenan induced rat paw edema tests respectively. Compounds 8, 9 and 11-13 and 15 were active
analgesic agents and compounds 8, 9 and 11-13 showed significant anti-inflammatory response in comparison
with control. Compounds 11 and 13 were screened for their ulcerogenic activities and none of them showed
significant ulcerogenic activity. The active Compounds 11 and 12 showed the highest drug likeness and drug
score.
Conclusions: The analgesic and anti-inflammatory activities of title compounds were comparable to that of
standard drug indomethacin with a safer profile of activity. The results revealed that both of oxadiazole and triazole
scaffolds can be determined as pharmacophores. The in silico predictions and pharmacological evaluations showed that
compounds 11 and 12 can be chosen as lead for further investigations.
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Cyclooxygenase (COX) and 5-Lipoxygenase (5-LO) are
two key enzymes that play important roles in the metab-
olism of arachidonic acid (AA) to pro-inflammatory
prostaglandins (PGs) and leukotrienes (LTs) respectively
[1]. It has been pointed out that inhibiting COX enzyme
could decrease cytoprotective PGs and increase the
conversion of AA to LTs by 5-LO enzyme which are
implicated in the ulceration induced by nonsteroidal
anti-inflammatory drugs (NSAIDs) [2,3]. Conversion of* Correspondence: almasirad.a@iaups.ac.ir
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stated.AA to Leukotrien B4 (LTB4) leads to hyperalgesic re-
sponse and related with rheumatoid arthritis and in-
flammatory bowel disease. However, dual inhibition of
COX and 5-LO would provide an anti-inflammatory
agent with better efficacy and fewer side effects [4-6].
During recent years, various structural families such as
di-tert-butylphenols, thiophene and pyrazoline deriva-
tives and modified NSAIDs have been investigated as
dual COX/5-LO inhibitors [7-9]. Amongst them several
1,3,4-oxadiazole, 1,3,4-triazole and hydrazone derivatives,
compounds 1 and 2 were dual COX, 5-LO inhibitors and
anti-inflammatory agents (Figure 1) [7-12]. As a part
of our ongoing research program to find novel anti-
inflammatory and analgesic compounds, herein,we describeral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
















Figure 1 Chemical structures of compounds 1 and 2 as dual COX/5-LO inhibitors and anti-inflammatory agents.
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rivatives which were designed by molecular hybridization
of previously described compounds, 1 and 2, in order to
evaluate the plausible pharmacophoric contribution of the
both imidazole and oxadiazole or triazole moieties in the
pharmacological activities. In silico toxicity risk assess-
ment and drug likeness predictions were done, in order to




Chemicals were purchased from Merck Chemical Com-
pany (Tehran, Iran) and carrageenan was prepared from
(Sigma-Aldrich, Dorset, UK). Melting points were taken
on an electrothermal IA 9300 capillary melting-point ap-
paratus (Ontario, Canada) and are uncorrected. 1H-
NMR spectra were obtained using a Bruker FT-400
spectrometer (Bruker, Rheinstetten, Germany). Tetra-
methyl silane was used as an internal standard. Mass
spectra were obtained using a 5973 Network Mass Se-
lective Detector at 70 eV (Agilent Technology). The FT-
IR spectra were obtained using a Shimadzu FT-IR 8400S
spectrographs (KBr disks).
5-Methyl-1H-Imidazole-4-carboxylic acid hydrazide (6)
To a stirring solution of ester 5 (10 g, 71.5 mmol) in
125 ml ethanol, at room temperature hydrazine hydrate
(50 ml, 1000 mmol) was added and refluxed for 48 h. The
resulting solution was concentrated, cooled and the pre-
cipitate was filtered, washed with dichloromethane and
crystallized in ethanol to give 6.73 g (74%) of 6, mp 214-
217°C. IR (KBr): υ cm-1 3326, 3270 (NH2, NH), 1656
(C = O). 1H-NMR(DMSO-d6): δ(ppm) 11.95 (bs, 1H,
NH), 8.61(bs, 1H, NH), 7.40(s, 1H, CH, imidazole),4.09(bs, 2H, NH2), 2.51(s, 3H, CH3). MS: m/z (%) 140(M+,
100), 109(78), 54(20).
2-Amino-5-(5-methy-1H-imidazol-4-yl)-1,3,4-oxadiazole (7)
To a stirring suspension of hydrazide 6 (500 mg, 3.57 mmol)
in dioxane (12 ml), sodium bicarbonate (300 mg) in water
(1 ml) was added at room temperature. The mixture was
stirred at room temperature for 5 min and cyanogen brom-
ide (386 mg, 3.64 mmol) was added. After 24 h stirring at
room temperature the solvent was evaporated and the
resulting precipitate was purified by crystallization in metha-
nol to give 400.7 mg(68%) of 7, mp 300-301°C. IR (KBr):
υ cm-1 3390, 3349 (NH2, NH), 3135 (C-H).
1H-NMR
(DMSO-d6): δ (ppm) 8.21 (bs, 1H, NH), 7.55(s, 1H,
CH, imidazole), 6.85(bs, 2H, NH2), 2.44(s, 3H, CH3).
MS: m/z (%) 165(M+, 18), 69(58), 45(100).
5-(5-Methyl-1H-imidazol-4-yl)-1,3,4-oxadiazole-2(3H)-thione (8)
A mixtue of hyrazide 6 (500 mg, 3.57 mmol), potassium
hydroxide (200 mg, 3.57 mmol), carbon disulfide (0.64 ml,
10.7 mmol) and ethanol (30 ml) was heated under reflux
for 72 h. The solution was acidified with dilute hydro-
chloric acid. The resulting precipitate was removed by fil-
tration and purified by crystallization in methanol to give
6.73 g (15%) of 8, mp 261-262°C. IR (KBr): υ cm-1 3477,
3281 (NH), 1626 (C =N), 1338 (C = S). 1H-NMR (DMSO-
d6): δ (ppm) 13.97 (bs, 1H, NH), 8.20(bs, 1H, NH), 7.71
(s, 1H, CH, imidazole), 2.43(s, 3H, CH3). MS: m/z (%)
182(M+, 100), 122(87), 109(100).
5-(5-Methyl-1H-imidazol-4-yl)-1,3,4-oxadiazole-2(3H)-one (9)
To a solution of compound 6 (550 mg, 4 mmol) and
triethyl amine (400 mg, 4 mmol) in DMF (50 ml), 1,1′-
carbonyldiimidazole (0.84 g, 5.1 mmol) was added in
one portion. The reaction mixture was refluxed for
Almasirad et al. DARU Journal of Pharmaceutical Sciences 2014, 22:22 Page 3 of 8
http://www.darujps.com/content/22/1/22one week. The volatiles were removed in vacuo, and
the residue was purified by TLC, eluting with ethyl
acetate-petroleum ether (1:1) to provide 78.7 mg (11%)
of 9, mp 298-299°C. IR (KBr): υ cm-1 3332(NH), 3206
(NH), 1714(C = O). 1H-NMR (DMSO-d6): δ (ppm) 9.1
(bs, 1H, NH), 8.1(bs, 1H,NH), 7.55(s, 1H, CH,




A solution of hydrazide 6 (500 mg, 3.57 mmol), potas-
sium thiocyanate (1 g, 10.71 mmol), concentrated hydro-
chloric acid (4 ml) and water 50 ml was stirred at room
temperature for 24 h. To the resulting suspension, so-
dium hydroxide 4% (60 ml) was added and stirred for
24 h at 60-70°C.The resulting mixture was neutralized
with hydrochloric acid and the resulting precipitate was
filtered, washed with acetone and purified by two times
crystallization in ethanol to give 219 mg (34%) of 10, mp
225-227°C. IR (KBr): υ cm-1 3400, 3134 (NH), 3114
(C-H), 1321 (C = S). 1H-NMR (DMSO-d6): δ (ppm)
13.87(bs, 1H, NH), 12.25(bs, 1H, NH), 9.1(bs, 1H, NH),
7.41(s, 1H, CH, imidazole), 2.31(s, 3H, CH3). MS:m/z (%)
181(M+, 13), 125(100), 107(90), 80(82), 67(58).
General procedures for the preparation of 4-substituted-
5-(5-methyl-1H-imidazol-4-yl)-4H-1,2,4-triazole-3-thiones
(11-15)
A mixture of compound 6 (500 mg, 3.57 mmol), corre-
sponding isothiocyanate derivative (3.6 mmol) and abso-
lute ethanol (5 ml) was stirred for 24 h. The resulting










Scheme 1 Synthesis of hydrazide 6. (a) CH3COOH, NaNO2, 0°C; (b) HCHadded to 3% sodium hydroxide solution (50 ml) and
refluxed for 24-48 h. The resulting solution was acidified
with hydrochloric acid, the precipitate was filtered, dried
and purified by crystallization.
4-Methyl-5-(5-methyl-1H-imidazol-4-yl)-4H-1,2,4-triazole-
3-thione (11)
Yield 34%; mp 225-227°C (ethanol). IR (KBr): υ cm1- 3376,
3149 (NH), 2526(weak, SH), 1337 (C = S). 1H–NMR
(DMSO-d6): δ(ppm) 12.12(bs, 1H, NH), 8.25(bs, 1H, NH),
7.72(s, 1H, CH, imidazole), 3.74(s, 3H, CH3), 2.37 (s, 3H,
CH3). MS: m/z (%) 195(M
+, 100), 122(25), 108(30).
4-phenyl-5-(5-methyl-1H-imidazol-4-yl)-4H-1,2,4-triazole-3-
thione (12)
Yield 13%; mp 275-277°C (THF/Water). IR (KBr): νcm1-
3477(NH), 3410(NH), 3118(C-H, aromatic), 1326 (C = S).
1H–NMR (DMSO-d6): δ (ppm) 12.39 (bs, 1H, NH), 8.5
(bs, 1H, NH), 7.6-7.2(m, 6H, aromatic and CH, imidazole),
2.26 (s, 1H, CH3). MS: m/z (%) 257(M




Yield 24%; mp 268-270°C (Methanol). IR (KBr): υ cm-1
3434(NH), 3210(NH), 3100(C-H,aromatic), 1340 (C = S).
1H–NMR (DMSO-d6): δ (ppm) 12.2(bs, 1H, NH), 8.5(bs,
1H, NH), 7.4(s, 1H, CH, imidazole), 7.3(d, J = 7.9Hz, 2H,
aromatic), 7.1(d, J = 7.9 Hz, 2H, aromatic), 2.34(s, 1H,














O, HCl, 0-5°C; NH3, 70°C; (c) NH2NH2.H2O, EtOH, reflux.
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1,2,4-triazole-3-thione (14)
Yield 18%; mp 140-142°C (Ethylacetate/Acetone). IR (KBr):
υ cm-1 3430(NH), 3216(NH), 3144(C-H,aromatic),
1311(C = S). 1H–NMR (DMSO-d6): δ (ppm) 12.8(bs,
1H, NH), 8.5(bs, 1H, NH), 7.4(s, 1H, CH, imidazole),
7.2(d, J = 8.4Hz, 2H, aromatic), 6.9(d, J = 8.4Hz, 2H,
aromatic), 3.76(s, 3H, OCH3), 2.27(s, 3H, CH3). MS:
m/z (%) 287(M+, 100), 106(22), 77(30).5-(5-Methyl-1H-imidazol-4-yl)-4-(4-fluorophenyl)-4H-
1,2,4-triazole-3-thione (15)
Yield 20%; mp 150-152°C (Methanol). IR (KBr): υ cm-1
3467 (NH), 3365 (NH), 3108(C-H, aromatic), 2520(weak,
SH), 1321 (C = S). 1H-NMR (DMSO-d6): δ (ppm) 12.4
(bs, 1H, NH), 8.5 (bs, 1H, NH), 7.8-7.3 (m, 5H, aromatic
and CH, imidazole), 2.25(s, 3H, CH3). MS: m/z (%) 275


























Scheme 2 Synthesis of target derivatives 7–15. (a) BrCN, Dioxane, rt; (b
(d) (1) KSCN, HCl, H2O, rt; (2) NaOH 3%, 60-70°C; (e) (1) Isothiocyanate derivPharmacology
Male NMRI mice (20-25 g) and Wistar rats (100-150 g)
were purchased from the animal breeding laboratories of
Pasteur Institute (Karaj, Iran). Each group consisted of
six animals. The animals were maintained in colony
cages at 25 ± 2°C, relative humidity 45–55%, under a
12 h light-dark cycle; they were fed standard animal feed.
All the animals were acclimatized for a week before use
and all ethical manners for use of laboratory animals
were considered carefully and the protocol was approved
by Islamic Azad University of Pharmaceutical Sciences
(IAUPS) ethical committee.Analgesic activity evaluation
Acetic acid writhing test was performed on mice and
indomethacin was used as standard drug [11]. Test com-
pounds and the standard drug were administered intraper-




























) CS2, KOH, EtOH, reflux; (c) 1,1′-CDI, triethylamine, DMF, reflux;
atives, EtOH, rt; (2) NaOH, reflux.
Table 1 Effects of new imidazolyl oxadiazole and triazole
derivatives, and Indomethacin in the inhibition of






Vehicle control 59.67 ± 6.8 - -
Indomethacin 13.50 ± 2.9 77.37 1***
7 44.33 ± 8.1 25.70 0.33
8 18.00 ± 3.7 69.83 0.90***
9 24.67 ± 5.5 58.65 0.76***
10 44.67 ± 2.8 25.14 0.32
11 23.83 ± 4.8 60.06 0.77***
12 24.33 ± 3.3 59.22 0.76***
13 17.67 ± 2.9 70.39 0.91***
14 ND4 - -
15 15.50 ± 3.9 74.02 0.96***
1All compounds were administered i.p. at the dose of 50 μmol/kg, number of
animals in each group n = 6.
2% of inhibition obtained by comparison with vehicle control group.
3Analgesic activity relative to Indomethacin,***P < 0.001 significant as
compared to control.
4Not determined.
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(0.6%, 0.1 ml/10 g) solution was administered ip 30
minutes after administration of compounds. The mean
number of writhes for each experimental group and per-
centage decrease, compared with that of the control group
were calculated during 30 minutes.
Anti-inflammatory activity against carrageenan induced
rat paw edema
Effective compounds in analgesic test were screened for
their anti-inflammatory activities using carrageenan in-
duced paw edema on wistar male rats [13]. The standard
and test groups received indomethacin as standard drug
or target compounds, 50 μmol/kg body weight (ip) sus-
pended in 4% tween in saline and the control animals re-
ceived 4% tween in saline respectively. One hour after
administration of drugs each rat received freshly pre-
pared 0.1% w/v aqueous solution of carrageenan in the
sub plantar region of right hind paw. The paw thickness
was measured from the ventral to the dorsal surfaces
using a dial caliper immediately prior to carrageenan in-
jection and then at each hour, up to 5 h after the sub
plantar injection. The edema was calculated as the thick-
ness variation between the carrageenan and saline treated
paw. Anti-inflammatory activity was expressed as the in-
hibition percent of the edema when compared with the
control group.
Ulcerogenic activity
The ulcerogenic activity of newly synthesized com-
pounds relative to known ulcerogenic drug, indometh-
acin was evaluated and scored by method of Cioli et al.
[14]. Wistar rats (160-180 g) were fasted for 24 h before
giving a single dose of each of vehicle, standard and test
compounds (105 mg/kg in 0.5% v/v CMC suspension,
peroral respectively and 17 h later, sacrificed under deep
ether anesthesia and stomachs were removed and then
examined by means of a magnifying glass to assess, the
incidence of redness and spot ulcers. For each stomach,
the mucosal damage was evaluated according to the fol-
lowing scoring system: 0.5: redness; 1.0: spot ulcers; 1.5:
hemorrhagic streaks; 2.0: ulcers >3 but ≤5; 3.0: ulcers > 5.
The mean score of each treated group minus the mean
score of control group was regarded as gastric mucosal ul-
ceration score.
In silico drug-score and toxicity assessments
Currently, there are several approaches to assess the
drug-likeness of the drug candidates [15,16]. One such
tool is the Osiris Property Explorer (OPE) a web based
system which is able to calculate properties such as
toxicity risk assessment and prediction of log p, solu-
bility (log s), fragment-based drug-likeness and overall
drug-score.Results and discussion
Chemistry
The target compounds were prepared according to the
Schemes 1 and 2. The ester 5 was synthesized as previ-
ously described method [17]. The key intermediate 6 was
prepared from the reaction of hydrazine hydrate with ester
5. Reaction of hydrazide 6 with cyanogens bromide gave
2-amino-1,3,4-oxadiazole 7 [18]. The 1,3,4-oxadiazole-
2-thone 8 and the 1,3,4-oxadiazole-2-one 9 were pre-
pared by the reaction of hydrazide 6 with KOH and
CS2 or 1,1′-carbonyldiimidazole (1,1′-CDI) in the pres-
ence of triethylamine respectively [18,19]. The 1,2,4-
triazole-3-thione 10 was synthesized via reaction of 6
with potassium thiocyanate and hydrochloric acid
followed by cyclization of thiosemicarbazide inter-
mediate with aqueous sodium hydroxide. Reaction of 6
with corresponding isothiocyanates yielded thiosemi-
carbazides as intermediate which were converted to 4-
substituted-1,2,4-triazole-3-thiones 11-15 in aqueous
sodium hydroxide [20-22]. The FCH group, Ukraine is
the supplier of compound 11 and the synthesis of
compound 12 has been previously reported [23].
Analgesic activity
The results of writhing test revealed that several synthe-
sized compounds 8, 9, 11-13 and 15 as well as indo-
methacin showed significant antinociceptive effect in
comparison with control (P < 0.001) (Table 1). In com-
pounds 7-9, existence of a more lipophilic group on the
position 2 of the oxadiazole ring lead to a more potent
Table 2 Effects of new imidazolyl, oxadiazole and triazole
derivatives 50(μmol/kg), and Indomethacin in the
Carrageenan-induced rat paw edema
Compound Time (h)1 Volume variation (μL)2,3 % inhibition4
Vehicle control 1 1.53 ± 0.12 -
2 1.84 ± 0.17 -
3 2.22 ± 0.24 -
4 2.44 ± 0.26 -
5 2.11 ± 0.21 -
Indomethacin 1 1.17 ± 0.01 23.53
2 1.35 ± 0.01 26.63
3 1.14 ± 0.02 48.6**
4 1.03 ± 0.02 57.79***
5 0.89 ± 0.01 57.82***
8 1 1.60 ± 0.15 -4.60
2 1.82 ± 0.16 1.10
3 1.68 ± 0.18 24.32
4 1.53 ± 0.21 37.30**
5 1.19 ± 0.18 43.60**
9 1 1.78 ± 0.14 -16.34
2 1.90 ± 0.14 -3.26
3 1.96 ± 0.16 11.71
4 1.78 ± 0.14 27.05
5 1.32 ± 0.07 37.44*
11 1 1.95 ± 0.04 -27.45
2 2.11 ± 0.06 -14.67
3 1.82 ± 0.16 18.02
4 1.67 ± 0.20 31.56*
5 1.38 ± 0.22 34.60*
12 1 1.27 ± 0.04 16.99
2 1.44 ± 0.06 21.74
3 1.49 ± 0.04 32.88*
4 1.45 ± 0.07 40.57*
5 1.22 ± 0.08 42.18*
13 1 1.19 ± 0.16 22.22
2 1.70 ± 0.15 7.60
3 1.55 ± 0.12 30.2*
4 1.66 ± 0.11 31.97*
5 1.41 ± 0.10 33.17*
14 1 1.39 ± 0.07 9.15
2 1.64 ± 0.10 10.87
3 1.90 ± 0.14 14.41
4 1.91 ± 0.11 21.72
5 1.69 ± 0.12 19.90
15 1 1.46 ± 0.08 4.57
2 1.78 ± 0.08 3.26
Table 2 Effects of new imidazolyl, oxadiazole and triazole
derivatives 50(μmol/kg), and Indomethacin in the
Carrageenan-induced rat paw edema (Continued)
3 1.96 ± 0.10 11.71
4 2.02 ± 0.26 17.21
5 1.98 ± 019 6.16
1Time after carrageenan injection (0.1 mg/paw), number of animals in each
group n = 6.
2All compounds were administered i.p, at the dose of 50 μmol/kg.
3Volume variation is the difference between the volumes of paw pre and post
of Carrageenan injection.
4% of inhibition obtained by comparison with vehicle control
group, *P < 0.05 , **p < 0.01, ***p < 0.001 significant from control.
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oxygen atom in compound 8 with NH to give compound
10, decreased the activity. Replacement of hydrogen
atom in 4th position of triazole ring with alkyl or aryl
groups, compounds 11-15 caused a noticeable analgesic
activity. The most potent analgesic derivative was 15 and
it can be concluded that existence of both electron with-
drawing and donating substituents on the para position
of the phenyl moiety (compounds 13 and 15 ) could en-
hance the analgesic activity of triazole derivatives.
Anti-inflammatory activity
In vivo anti-inflammatory evaluation of target com-
pounds is summarized in Table 2. Compounds 8-9 and
11-13 were active anti-inflammatory agents (33-43% in-
hibition) after 5 h in comparison with control and their
activity was comparable to indomethacin. As shown in
Table 2, there wasn't any significant difference between
the activity of compounds 9, 11 and 13 and the most ac-
tive derivatives were 8 and 12. Similar to analgesic activ-
ity results, it can be deduced by comparison of these
data that the best substituent on position 2 of oxadiazole
ring is a sufur moiety. In contrast to analgesic activity,
the introduction of electron donating or withdrawing
moieties on the para position of phenyl ring has a dele-
terious effect on the anti-inflammatory activity.
Ulcerogenic activity
The compounds 11 and 13 as two active derivatives, in
anti-Inflammatory and analgesic tests respectively, were
evaluated for their acute ulcerogenic activity. A significantTable 3 Acute ulcerogenic activity of compounds (11 and
13) in the method of Cioli
Compound Dose (mg/kg)1 Ulcerogenic activity
(Severity index ± SEM)
P value
11 105 0.50 ± 0.01 p > 0.05
13 105 0.58 ± 0.08 p > 0.05
Indomethacin 105 1.67 ± 0.333 P* < 0.001
Control - 0.00 ± 0.00 -
1number of animals in each group n = 6, *p < 0.001 significant from control.
Table 4 Drug-likeness of target compounds predicted by Osiris Property Explorer tool in comparison with
indomethacin and celecoxib
Compound Toxicity risk1 cLogP Solubility MW Drug- likeness Drug-score
M2 T3 I4 R5
7 - - - - 0.06 -2.57 165 -1.88 0.54
8 - - - - 0.92 -2.2 182 0.87 0.81
9 - - - - 0.25 -2.12 166 -1.75 0.55
10 - - - - 0.75 -2.06 181 1.39 0.86
11 - - - - 1.04 -1.7 195 2.39 0.94
12 - - - - 2.29 -3.55 257 2.46 0.82
13 - - - - 2.61 -3.89 271 0.76 0.68
14 + ± - - 2.19 -3.56 287 0.7 0.34
15 - - - - 2.35 -3.86 275 0.7 0.69
Indomethacin - - - - 3.83 -5.4 357 7.59 0.57
Celecoxib - - - - 2.27 -5.4 365 -9.50 0.31
1Ranked according to: (-) no bad effect, (±) medium bad effect, (+) bad effect; 2 M, Mutagenic effect; 3 T, Tumorgenic effect; 4I, Irritating effect;
5R, Reproductive effect.
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ation score between 0.50 ± 0.01 and 0.58 ± 0.08.
was observed in the tested compounds. In fact, not
only the standard drug, indomethacin showed a high
score of 1.67 ± 0.33, but also none of these two evaluated
derivatives induced significant ulceration in comparison
to control (Table 3).In silico drug-likeness and toxicity results
In this work, open-source program OPE was used to
evaluate the fragment-based drug-likeness of title com-
pounds and comparing them with indomethacin and cel-
ecoxib. The overall drug-score which was mentioned
earlier combines drug-likeness, clogp, clogs, molecular
weight and toxicity risk factors in one single value,
where the occurrence frequency of each fragment is de-
termined within the collection of approved drugs and
within the supposedly non-drug like chemicals of fluka
company. A positive drug-likeness value (0.1-10) states
that a molecule contains fragments which are present in
commercial drugs. The OPE study revealed that except
compound 14 which showed high risk of mutagenic and
medium risk of tumorgenic effects, all compounds,
indomethacin and celecoxib are supposed to be non-
mutagenic, non-tumorgenic, non-irritant with no reproduct-
ive effects. The in silico drug-relevant properties obtained by
OPE are given in Table 4. The potential drug-likeness values
of all designed compounds were significantly higher than
that of celecoxib but this value for compounds 7 and 9 is
negative so their similarity to commercial chemicals is more
than traded drugs. Generally, the drug-score values of com-
pounds 7-15 (0.34-0.94) were more than that of celecoxib
(0.31) and these scores for compounds 8, 10-13 and 15(0.68-0.94) were more than indomethacin and for com-
pounds 7 and 9 comparable with indomethacin.Conclusion
A series of new methyl-imidazolyl-1,3,4-oxadiazoles and
1,2,4-triazoles were designed and synthesized. The in vivo
analgesic, anti-inflammatory and ulcerogenic evaluations,
revealed that most of them were active in both tests with-
out any ulcerogenic potential in comparison to control.
The results revealed that both of oxadiazole and triazole
scaffolds can be determined as pharmacophores. However,
compounds 11 and 12 showed the highest values of drug-
likeness and drug-score and acceptable pharmacological
activity in both tests, so they could be selected as lead
compounds for further modifications.Statistics
Statistics were performed with one-way analysis of vari-
ance (ANOVA), which was followed by Tukey multi-
comparison test. All data are presented as mean ± SEM,
p < 0.05 was considered to be significant.
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